Subsidy Information and Financing Scheme MAFZanubrutinib Capsule 80 mg 1) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior thera... See all × MAFZanubrutinib Capsule 80 mg 1) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. 2) Monotherapy for patients with Waldenstrom’s macroglobulinemia (WM) who have received at least one prior therapy. 3) Monotherapy for previously untreated Waldenstrom’s macroglobulinemia (WM) in patients who are unsuitable for chemo-immunotherapy. 4) Monotherapy for relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based regimen. 5) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. 6) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. MSHLZanubrutinib Capsule 80 mg 1) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior thera... See all × MSHLZanubrutinib Capsule 80 mg 1) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. 2) Monotherapy for patients with Waldenstrom’s macroglobulinemia (WM) who have received at least one prior therapy. 3) Monotherapy for previously untreated Waldenstrom’s macroglobulinemia (WM) in patients who are unsuitable for chemo-immunotherapy. 4) Monotherapy for relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based regimen. 5) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. 6) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.
Post Marketing Information DHCPL 02/02/2026 Correction to the Singapore Prescribing Information for Brukinsa® Capsule 80mg on the dosage modifications for use with CYP3A inhibitors
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 80 mg National Cancer Centre National University Hospital Singapore General Hospital Tan Tock Seng Hospital